ARWR — Arrowhead Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $8.26bn
- $7.92bn
- $829.45m
Arrowhead climbs on licensing agreement with Novartis for upto $2 billion
U.S. STOCKS ON THE MOVE-United Therapeutics, Signet Jewelers, Arrowhead
Arrowhead climbs on licensing agreement with Novartis for upto $2 billion
Arrowhead and Novartis agree up to $2 billion deal for license to neuromuscular therapy (updated)
Arrowhead and Novartis agree up to $2 billion deal for license to neuromuscular therapy
Sarepta rises on genetic therapy progress
Arrowhead Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Arrowhead Pharma Q3 revenue beats estimates
Brief: Arrowhead Subsidiary Visirna Sells Rights To Hypertriglyceridemia Candidate Plozasiran In Greater China To Sanofi
Sarepta shares rebound after shipments of gene therapy Elevidys resume in US (updated)
Brief: Arrowhead Pharmaceuticals Expects $200 Million Milestone By End Of 2025
U.S. STOCKS ON THE MOVE-Tesla, Northern Trust, General Dynamics
U.S. STOCKS ON THE MOVE-Lamb Weston, Arrowhead Pharma, Cal-Maine
Arrowhead gains as milestone payments from Sarepta still expected
Sarepta's licensing partner Arrowhead expects near-term payments despite setbacks (updated)
Brief: Arrowhead Pharmaceuticals Issues Statement On Status Of Ongoing Agreement With Sarepta Therapeutics
Brief: Arrowhead Expects Sarepta To Meet Financial Obligations Under License Agreement
Sarepta's licensing patner Arrowhead expects near-term payments despite setbacks
Arrowhead Pharma tumbles on Sarepta partnership payment fears after safety crisis